NASDAQ:SCMP - Sucampo Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.00 0.00 (0.00 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$18.00
Today's RangeN/A
52-Week Range$9.30 - $18.75
VolumeN/A
Average Volume2.56 million shs
Market Capitalization$839.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38
Sucampo Pharmaceuticals logoSucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Receive SCMP News and Ratings via Email

Sign-up to receive the latest news and ratings for SCMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SCMP
CUSIP86490910
Phone+1-301-9613400

Debt

Debt-to-Equity Ratio7.37
Current Ratio5.11
Quick Ratio4.46

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio16.07
P/E Growth5.06

Sales & Book Value

Annual Sales$230.06 million
Price / Sales3.69
Cash Flow$2.4096 per share
Price / Cash7.47
Book Value$3.60 per share
Price / Book5.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$18.48 million
Net Margins16.92%
Return on Equity126.04%
Return on Assets11.04%

Miscellaneous

Employees139
Outstanding Shares47,170,000

Sucampo Pharmaceuticals (NASDAQ:SCMP) Frequently Asked Questions

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) released its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.25 by $0.02. The biopharmaceutical company earned $61.27 million during the quarter, compared to analysts' expectations of $58.05 million. Sucampo Pharmaceuticals had a return on equity of 126.04% and a net margin of 16.92%. The business's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.30 earnings per share. View Sucampo Pharmaceuticals' Earnings History.

What price target have analysts set for SCMP?

8 analysts have issued 1 year price objectives for Sucampo Pharmaceuticals' stock. Their predictions range from $15.00 to $43.00. On average, they expect Sucampo Pharmaceuticals' share price to reach $22.8750 in the next twelve months. View Analyst Ratings for Sucampo Pharmaceuticals.

What are Wall Street analysts saying about Sucampo Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Sucampo’s pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of Amitizia in pediatric functional constipation is under review. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. Moreover, Sucampo discontinued Amitzia’s sprinkle formulation development as it did not meet bioequivalence with capsule formulation. Shares of the company have outperformed the industry. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters." (2/9/2018)
  • 2. Maxim Group analysts commented, "Sucampo’s stock has risen sharply in the past few weeks (from ~$10 to $16+) on no new fundamental news. However, a Bloomberg story has been circulating that the company may be entertaining suitors. We have no specific knowledge to confirm this, but do see an undervalued company that is generating free cash flow and has a strong (orphan) pipeline. Our last note (from 11/21) reviewed the R&D Day which focused on two key pipeline products, VTS-270 (Neeman Pick Disease) and CPP-1X/sulindac (Familial Adenomatous Polyposis )." (12/7/2017)

Who are Sucampo Pharmaceuticals' key executives?

Sucampo Pharmaceuticals' management team includes the folowing people:
  • Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)
  • Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)
  • Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)
  • Matthias Alder, Executive Vice President (Age 52)
  • Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)
  • Alex Driggs, General Counsel, Corporate Secretary (Age 41)
  • Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)
  • John H. Johnson, Lead Independent Director (Age 58)
  • Paul R. Edick, Director (Age 62)
  • Daniel P. Getman Ph.D., Director (Age 59)

Has Sucampo Pharmaceuticals been receiving favorable news coverage?

News headlines about SCMP stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sucampo Pharmaceuticals earned a news sentiment score of 0.17 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 47.14 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Sucampo Pharmaceuticals?

Shares of SCMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sucampo Pharmaceuticals' stock price today?

One share of SCMP stock can currently be purchased for approximately $18.00.

How big of a company is Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals has a market capitalization of $839.46 million and generates $230.06 million in revenue each year. Sucampo Pharmaceuticals employs 139 workers across the globe.

How can I contact Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected]


MarketBeat Community Rating for Sucampo Pharmaceuticals (SCMP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  503
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.